<p>Soleno Therapeutics, Inc. (NASDAQ:SLNO - 获取免费报告) 的股价在周四交易前出现跳涨。该股票此前收于 50.00 美元，但开盘价为 53.33 美元。Soleno Therapeutics 的股票最后交易价格为 49.7560 美元，成交量为 859,773 股。</p>
<p>获取 <strong>Soleno Therapeutics</strong> 的提醒：</p>
<h2>华尔街分析师预测增长</h2>
<p>一些研究分析师最近对 SLNO 股票发表了评论。Wall Street Zen 在 11 月 8 日的报告中将 Soleno Therapeutics 的评级从 “持有” 上调至 “买入”。高盛集团在 10 月 7 日的研究报告中对 Soleno Therapeutics 的股票设定了 125.00 美元的目标价，并给予该股票 “买入” 评级。HC Wainwright 在 8 月 18 日的报告中重申了 “买入” 评级，并将 Soleno Therapeutics 的目标价从 100.00 美元上调至 110.00 美元。富国银行在 11 月 5 日的报告中重申了 “增持” 评级，并将 Soleno Therapeutics 的目标价从 123.00 美元下调至 106.00 美元。最后，Lifesci Capital 在 9 月 10 日的报告中将 Soleno Therapeutics 的股票评级上调至 “强力买入”。两位分析师给予该股票 “强力买入” 评级，十二位分析师给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，Soleno Therapeutics 目前的平均评级为 “买入”，共识目标价为 111.46 美元。</p>
<p><strong>查看我们对 Soleno Therapeutics 的最新分析</strong></p>
<h2>Soleno Therapeutics 股票表现</h2>
<p>该公司的 50 日简单移动平均线为 56.34 美元，200 日简单移动平均线为 68.73 美元。公司的流动比率为 16.08，速动比率为 15.88，债务与股本比率为 0.10。该股票的市值为 26.6 亿美元，市盈率为-26.90，贝塔值为-3.15。</p>
<p>Soleno Therapeutics (NASDAQ:SLNO - 获取免费报告) 最近在 11 月 4 日发布了其财报。公司报告本季度每股收益为 0.47 美元，超出分析师一致预期的 0.08 美元，超出幅度为 0.39 美元。该公司本季度的收入为 6602 万美元，而分析师预期为 4746 万美元。整体来看，卖方分析师预计 Soleno Therapeutics, Inc.在本年度将发布-3.72 美元的每股收益。</p>
<h2>Soleno Therapeutics 的机构交易</h2>
<p>机构投资者最近对该公司的持仓进行了调整。Wellington Management Group LLP 在第三季度将其在 Soleno Therapeutics 的持股增加了 272.3%。Wellington Management Group LLP 目前拥有 2312095 股该公司的股票，价值 156298000 美元，此前在上个季度又购买了 1691057 股。Adage Capital Partners GP L.L.C.在第一季度将其在 Soleno Therapeutics 的持股增加了 58.2%。Adage Capital Partners GP L.L.C.目前拥有 4392696 股该公司的股票，价值 313858000 美元，此前在上个季度又收购了 1616720 股。Braidwell LP 在第三季度获得了 Soleno Therapeutics 的新头寸，价值约为 86662000 美元。Invesco Ltd.在第三季度将其在 Soleno Therapeutics 的持股增加了 132.3%。Invesco Ltd.目前拥有 1500525 股该公司的股票，价值 101435000 美元，此前在上个季度又购买了 854551 股。最后，Price T Rowe Associates Inc. MD 在第一季度将其在 Soleno Therapeutics 的持股增加了 47.2%。Price T Rowe Associates Inc. MD 目前拥有 2400418 股该公司的股票，价值 171510000 美元，此前在上个季度又购买了 769700 股。97.42% 的股票目前由机构投资者和对冲基金持有。</p>
<h2>关于 Soleno Therapeutics</h2>
<p>(获取免费报告)</p>
<p>Soleno Therapeutics, Inc.是一家临床阶段的生物制药公司，专注于开发和商业化用于治疗罕见疾病的新型疗法。其主要候选药物是氟氯噻吨氯化物缓释片，这是一种每日一次的口服药物，目前正在进行治疗普拉德 - 威利综合症的第三阶段临床试验。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Soleno Therapeutics 更好</li>
<li>使用 MarketBeat 股息收益计算器</li>
<li>三只冬季股票具有良好的增长机会</li>
<li>三只国防股票将受益于军事支出增加</li>
<li>2026 年反弹股票：三只标普滞后股有望突破</li>
<li>投资者最重要的沃伦·巴菲特股票：他自己的股票</li>
<li>特斯拉多头看到 500 美元的前景——但空头警告痛苦的反转</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Soleno Therapeutics 吗？</h2>
<p>在考虑 Soleno Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Soleno Therapeutics 并不在名单上。</p>
<p>虽然 Soleno Therapeutics 目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

Soleno治疗

<p>Soleno Therapeutics（纳斯达克代码：SLNO）股票跳空高开，开盘价为 53.33 美元，前一交易日收盘价为 50.00 美元，最后交易价为 49.7560 美元。分析师对该股票给予了一致的 “买入” 评级，目标价为 111.46 美元。公司报告了强劲的财报，盈利每股 0.47 美元，收入为 6602 万美元，均超出预期。机构投资者显著增加了对公司的持股。Soleno Therapeutics 专注于开发罕见疾病的治疗方案，其主要候选药物正在进行针对普拉德 - 威利综合症的第三阶段临床试验</p>

<p>Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report)'s stock price gapped up prior to trading on Thursday . The stock had previously closed at $50.00, but opened at $53.33. Soleno Therapeutics shares last traded at $49.7560, with a volume of 859,773 shares.</p>
<div class="lb-trans"><p>Soleno Therapeutics, Inc. (NASDAQ:SLNO - 获取免费报告) 的股价在周四交易前出现跳涨。该股票此前收于 50.00 美元，但开盘价为 53.33 美元。Soleno Therapeutics 的股票最后交易价格为 49.7560 美元，成交量为 859,773 股。</p>
</div><p>Get <strong>Soleno Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Soleno Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of research analysts have recently commented on SLNO shares. Wall Street Zen raised Soleno Therapeutics from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday, November 8th. The Goldman Sachs Group set a $125.00 price objective on shares of Soleno Therapeutics and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, October 7th. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $110.00 price objective (up from $100.00) on shares of Soleno Therapeutics in a report on Monday, August 18th. Wells Fargo &amp; Company reiterated an &#34;overweight&#34; rating and issued a $106.00 target price (down previously from $123.00) on shares of Soleno Therapeutics in a report on Wednesday, November 5th. Finally, Lifesci Capital upgraded shares of Soleno Therapeutics to a &#34;strong-buy&#34; rating in a report on Wednesday, September 10th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Soleno Therapeutics presently has an average rating of &#34;Buy&#34; and a consensus price target of $111.46.</p>
<div class="lb-trans"><p>一些研究分析师最近对 SLNO 股票发表了评论。Wall Street Zen 在 11 月 8 日的报告中将 Soleno Therapeutics 的评级从 “持有” 上调至 “买入”。高盛集团在 10 月 7 日的研究报告中对 Soleno Therapeutics 的股票设定了 125.00 美元的目标价，并给予该股票 “买入” 评级。HC Wainwright 在 8 月 18 日的报告中重申了 “买入” 评级，并将 Soleno Therapeutics 的目标价从 100.00 美元上调至 110.00 美元。富国银行在 11 月 5 日的报告中重申了 “增持” 评级，并将 Soleno Therapeutics 的目标价从 123.00 美元下调至 106.00 美元。最后，Lifesci Capital 在 9 月 10 日的报告中将 Soleno Therapeutics 的股票评级上调至 “强力买入”。两位分析师给予该股票 “强力买入” 评级，十二位分析师给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，Soleno Therapeutics 目前的平均评级为 “买入”，共识目标价为 111.46 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Soleno Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Soleno Therapeutics 的最新分析</strong></p>
</div><h2>Soleno Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Soleno Therapeutics 股票表现</h2>
</div><p>The firm has a fifty day simple moving average of $56.34 and a 200 day simple moving average of $68.73. The company has a current ratio of 16.08, a quick ratio of 15.88 and a debt-to-equity ratio of 0.10. The stock has a market cap of $2.66 billion, a price-to-earnings ratio of -26.90 and a beta of -3.15.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为 56.34 美元，200 日简单移动平均线为 68.73 美元。公司的流动比率为 16.08，速动比率为 15.88，债务与股本比率为 0.10。该股票的市值为 26.6 亿美元，市盈率为-26.90，贝塔值为-3.15。</p>
</div><p>Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last issued its earnings results on Tuesday, November 4th. The company reported $0.47 EPS for the quarter, beating analysts' consensus estimates of $0.08 by $0.39. The firm had revenue of $66.02 million during the quarter, compared to analyst estimates of $47.46 million. As a group, sell-side analysts expect that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current year.</p>
<div class="lb-trans"><p>Soleno Therapeutics (NASDAQ:SLNO - 获取免费报告) 最近在 11 月 4 日发布了其财报。公司报告本季度每股收益为 0.47 美元，超出分析师一致预期的 0.08 美元，超出幅度为 0.39 美元。该公司本季度的收入为 6602 万美元，而分析师预期为 4746 万美元。整体来看，卖方分析师预计 Soleno Therapeutics, Inc.在本年度将发布-3.72 美元的每股收益。</p>
</div><h2>Institutional Trading of Soleno Therapeutics</h2>
<div class="lb-trans"><h2>Soleno Therapeutics 的机构交易</h2>
</div><p>Institutional investors have recently made changes to their positions in the business. Wellington Management Group LLP raised its holdings in shares of Soleno Therapeutics by 272.3% in the third quarter. Wellington Management Group LLP now owns 2,312,095 shares of the company's stock valued at $156,298,000 after buying an additional 1,691,057 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its stake in shares of Soleno Therapeutics by 58.2% in the first quarter. Adage Capital Partners GP L.L.C. now owns 4,392,696 shares of the company's stock worth $313,858,000 after acquiring an additional 1,616,720 shares during the last quarter. Braidwell LP acquired a new position in shares of Soleno Therapeutics during the third quarter worth approximately $86,662,000. Invesco Ltd. grew its stake in shares of Soleno Therapeutics by 132.3% during the third quarter. Invesco Ltd. now owns 1,500,525 shares of the company's stock valued at $101,435,000 after purchasing an additional 854,551 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Soleno Therapeutics by 47.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,400,418 shares of the company's stock valued at $171,510,000 after purchasing an additional 769,700 shares during the last quarter. 97.42% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>机构投资者最近对该公司的持仓进行了调整。Wellington Management Group LLP 在第三季度将其在 Soleno Therapeutics 的持股增加了 272.3%。Wellington Management Group LLP 目前拥有 2312095 股该公司的股票，价值 156298000 美元，此前在上个季度又购买了 1691057 股。Adage Capital Partners GP L.L.C.在第一季度将其在 Soleno Therapeutics 的持股增加了 58.2%。Adage Capital Partners GP L.L.C.目前拥有 4392696 股该公司的股票，价值 313858000 美元，此前在上个季度又收购了 1616720 股。Braidwell LP 在第三季度获得了 Soleno Therapeutics 的新头寸，价值约为 86662000 美元。Invesco Ltd.在第三季度将其在 Soleno Therapeutics 的持股增加了 132.3%。Invesco Ltd.目前拥有 1500525 股该公司的股票，价值 101435000 美元，此前在上个季度又购买了 854551 股。最后，Price T Rowe Associates Inc. MD 在第一季度将其在 Soleno Therapeutics 的持股增加了 47.2%。Price T Rowe Associates Inc. MD 目前拥有 2400418 股该公司的股票，价值 171510000 美元，此前在上个季度又购买了 769700 股。97.42% 的股票目前由机构投资者和对冲基金持有。</p>
</div><h2>About Soleno Therapeutics</h2>
<div class="lb-trans"><h2>关于 Soleno Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.</p>
<div class="lb-trans"><p>Soleno Therapeutics, Inc.是一家临床阶段的生物制药公司，专注于开发和商业化用于治疗罕见疾病的新型疗法。其主要候选药物是氟氯噻吨氯化物缓释片，这是一种每日一次的口服药物，目前正在进行治疗普拉德 - 威利综合症的第三阶段临床试验。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Soleno Therapeutics</li>
<li>Using the MarketBeat Dividend Yield Calculator</li>
<li>Top 3 Winter Stocks With Solid Growth Opportunities</li>
<li>3 Defense Stocks Set to Benefit From Increased Military Spending</li>
<li>2026 Comeback Picks: 3 S&amp;P Laggards Poised to Break Out</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>Tesla Bulls See $500 Ahead—But Bears Warn of a Painful Reversal</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Soleno Therapeutics 更好</li>
<li>使用 MarketBeat 股息收益计算器</li>
<li>三只冬季股票具有良好的增长机会</li>
<li>三只国防股票将受益于军事支出增加</li>
<li>2026 年反弹股票：三只标普滞后股有望突破</li>
<li>投资者最重要的沃伦·巴菲特股票：他自己的股票</li>
<li>特斯拉多头看到 500 美元的前景——但空头警告痛苦的反转</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Soleno Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Soleno Therapeutics 吗？</h2>
</div><p>Before you consider Soleno Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Soleno Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Soleno Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Soleno Therapeutics 并不在名单上。</p>
</div><p>While Soleno Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Soleno Therapeutics 目前在分析师中获得 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Soleno 治疗（NASDAQ:SLNO）股票跳空高开 - 接下来会发生什么？